Antemortem CSF A<i>β</i>42/A<i>β</i>40 ratio predicts Alzheimer's disease pathology better than A<i>β</i>42 in rapidly progressive dementias

Abstract

The present data support the use of CSF A<i>β</i>42/A<i>β</i>40 ratio as a biomarker of AD pathophysiology and noninvasive screener for A<i>β</i> pathology burden, and its introduction in the research diagnostic criteria for AD.